Data gathered: April 15
Alternative Data for Virpax Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | N/A | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,772 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,386 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 10 | Sign up | Sign up | Sign up |
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
| Price | $0.26 |
| Target Price | Sign up |
| Volume | 29,380 |
| Market Cap | $830,000 |
| Year Range | $0.23 - $30 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Virpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 17 - Thefly.com |
 |
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain CandidateFebruary 14 - Biztoc.com |
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On OfferingJanuary 30 - GlobeNewswire |
|
 |
Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with ConditionsJanuary 9 - ETF Daily News |
|
Amendments to Independent Contractor Agreements at Virpax Pharmaceuticals Clarify Roles and ResponsibilitiesJanuary 1 - ETF Daily News |
Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsightApril 8 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 780,000 | -780,000 | -2M | -1.9M | -0.431 |
| Q2 '24 | 0 | 1.5M | -1.5M | -3.5M | -3.5M | -1.750 |
| Q1 '24 | 0 | 1.7M | -1.7M | -3.2M | -3.3M | -2.750 |
| Q4 '23 | 0 | 3.4M | -3.8M | -4.6M | -4.6M | -3.900 |
| Q3 '23 | 120,000 | 6.6M | -6.5M | -6M | -6.1M | -0.510 |
Insider Transactions View All
| Sendrow Jerrold filed to buy 9,006 shares at $1.3. May 26 '22 |
| Floyd Eric filed to buy 8,018 shares at $1.4. May 20 '22 |
| Mack Anthony P. filed to buy 252,562 shares at $1.3. May 20 '22 |
Similar companies
Read more about Virpax Pharmaceuticals (VRPX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Virpax Pharmaceuticals?
The Market Cap of Virpax Pharmaceuticals is $830,000.
What is the current stock price of Virpax Pharmaceuticals?
Currently, the price of one share of Virpax Pharmaceuticals stock is $0.26.
How can I analyze the VRPX stock price chart for investment decisions?
The VRPX stock price chart above provides a comprehensive visual representation of Virpax Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Virpax Pharmaceuticals shares. Our platform offers an up-to-date VRPX stock price chart, along with technical data analysis and alternative data insights.
Does VRPX offer dividends to its shareholders?
As of our latest update, Virpax Pharmaceuticals (VRPX) does not offer dividends to its shareholders. Investors interested in Virpax Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Virpax Pharmaceuticals?
Some of the similar stocks of Virpax Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.